IPSC - Financial Snapshot

📈 Metrics for IPSC

Price	$0.49
netCurrentAssetsPerShare	$0.99 netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
netTangibleAssetsPerShare	$2.04 netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
maxEarningPowerPerShare	$-3.05 maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
adjustedEarningPower	$-3.16 adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
nonCashChargeToMKTCAP	6.85% nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
cashValuePerShare	$1.04 cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding

Data as of: Price 08-29-25 16:00 ET, Balance Sheet 2025-06-30, Income Statement 2025-06-30

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.